Acute Effects of High- vs. Low-frequency Vibration Foam Rolling

June 26, 2025 updated by: Erhan Seçer, Celal Bayar University

Acute Effects of High- vs. Low-frequency Vibration Foam Rolling on Flexibility, Dynamic Balance and Vertical Jump in Young Male Recreational Athletes: a Randomized Controlled Cross-over Study Design

This study aims to compare the acute effects of low- and high-frequency vibration foam rolling on flexibility, dynamic balance, and vertical jump in young male recreational athletes. Fourteen athletes will be included in this study, planned as a randomized controlled cross-over study. All athletes wil be completed three interventions: 1) low-frequency vibration foam rolling (LFVFR), 2) high-frequency vibration foam rolling (HFVFR), 3) rest control. Pre- and post-test assessment will be included flexibilty, assessed with the sit-and-reach test; dynamic balance, assessed with the Y balance test; and vertical jump, assessed with the vertical jump test.

Study Overview

Status

Status

Indicates the current recruitment status or the expanded access status.
Completed

Conditions

Conditions

The disease, disorder, syndrome, illness, or injury that is being studied. On ClinicalTrials.gov, conditions may also include other health-related issues, such as lifespan, quality of life, and health risks.

Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.

Study Type

Study Type

Describes the nature of a clinical study. Study types include interventional studies (also called clinical trials), observational studies (including patient registries), and expanded access.
Interventional

Enrollment (Actual)

Enrollment

The number of participants in a clinical study. The "anticipated" enrollment is the target number of participants that the researchers need for the study.
14

Phase

Phase

The stage of a clinical trial studying a drug or biological product, based on definitions developed by the U.S. Food and Drug Administration (FDA). The phase is based on the study's objective, the number of participants, and other characteristics. There are five phases: Early Phase 1 (formerly listed as Phase 0), Phase 1, Phase 2, Phase 3, and Phase 4. Not Applicable is used to describe trials without FDA-defined phases, including trials of devices or behavioral interventions.
  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Turkey
      • Manisa, Turkey, 45030
        • Manisa Celal Bayar University

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Eligibility Criteria

The key requirements that people who want to participate in a clinical study must meet or the characteristics they must have. Eligibility criteria consist of both inclusion criteria (which are required for a person to participate in the study) and exclusion criteria (which prevent a person from participating). Types of eligibility criteria include whether a study accepts healthy volunteers, has age or age group requirements, or is limited by sex.

Ages Eligible for Study

  • Adult

Accepts Healthy Volunteers

Yes

Description

Inclusion Criteria:

  • To volunteer to participate in the study
  • To engage in sports activities at least 2-3 days a week

Exclusion Criteria:

  • Players with a history of major sports injury or time-loss injury that required surgery
  • Musculoskeletal problems that compromised their performance in the study
  • A history of lower extremity pathology in the 3 months before the study
  • used any drugs or supplements

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Health Services Research
  • Allocation: Randomized
  • Interventional Model: Crossover Assignment
  • Masking: Single

Arms and Interventions

Participant Group / Arm

Participant Group / Arm

A group or subgroup of participants in a clinical trial that receives a specific intervention/treatment, or no intervention, according to the trial's protocol.
Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.
No Intervention: Control Group
No intervention will be applied to the control group.
Active Comparator: HFVFR Group
Athletes will be performed three sets of HFVFR for 30 s, with a 30 s break between each set and exercise. The rolling frequency will be standardized using a metronome set at 60 beats per minute. Athletes will be instructed to roll at a velocity of two metronome beats for each rolling direction. Intensity of pressure will be controlled with a target rating of 7 of 10 on a Numerical Rating Scale (0 = no discomfort and 10 = maximum discomfort) during HFVFR intervention. The target muscle groups and/or body sides will be anterior thigh, posterior thigh, posterior calf, iliotibial-band, and gluteals (buttocks).During HFVFR, the vibrator booster will be set to a frequency of 67 hz, which is within the optimal frequency range (12 to 90 hz) to influence musculoskeletal system, and an amplitude of 1.95 mm.
Other: High-frequency vibration foam rolling
Athletes will be performed three sets of HFVFR for 30 s, with a 30 s break between each set and exercise. The rolling frequency will be standardized using a metronome set at 60 beats per minute. Athletes will be instructed to roll at a velocity of two metronome beats for each rolling direction. Intensity of pressure will be controlled with a target rating of 7 of 10 on a Numerical Rating Scale (0 = no discomfort and 10 = maximum discomfort) during HFVFR intervention. The target muscle groups and/or body sides will be anterior thigh, posterior thigh, posterior calf, iliotibial-band, and gluteals (buttocks).During HFVFR, the vibrator booster will be set to a frequency of 67 hz, which is within the optimal frequency range (12 to 90 hz) to influence musculoskeletal system, and an amplitude of 1.95 mm.
Active Comparator: LFVFR Group
Athletes will be performed three sets of LFVFR for 30 s, with a 30 s break between each set and exercise. The rolling frequency will be standardized using a metronome set at 60 beats per minute. Athletes will be instructed to roll at a velocity of two metronome beats for each rolling direction. Intensity of pressure will be controlled with a target rating of 7 of 10 on a Numerical Rating Scale (0 = no discomfort and 10 = maximum discomfort) during LFVFR intervention. The target muscle groups and/or body sides will be anterior thigh, posterior thigh, posterior calf, iliotibial-band, and gluteals (buttocks).During LFVFR, the vibrator booster will be set to a frequency of 35 hz, which is within the optimal frequency range (12 to 90 hz) to influence musculoskeletal system, and an amplitude of 1.95 mm.
Other: Low-frequency vibration foam rolling
Athletes will be performed three sets of LFVFR for 30 s, with a 30 s break between each set and exercise. The rolling frequency will be standardized using a metronome set at 60 beats per minute. Athletes will be instructed to roll at a velocity of two metronome beats for each rolling direction. Intensity of pressure will be controlled with a target rating of 7 of 10 on a Numerical Rating Scale (0 = no discomfort and 10 = maximum discomfort) during LFVFR intervention. The target muscle groups and/or body sides will be anterior thigh, posterior thigh, posterior calf, iliotibial-band, and gluteals (buttocks).During LFVFR, the vibrator booster will be set to a frequency of 35 hz, which is within the optimal frequency range (12 to 90 hz) to influence musculoskeletal system, and an amplitude of 1.95 mm.

What is the study measuring?

Primary Outcome Measures

Primary Outcome Measures

In a clinical study's protocol, the planned outcome measure that is the most important for evaluating the effect of an intervention/treatment. Most clinical studies have one primary outcome measure, but some have more than one.
Outcome Measure
Measure Description
Time Frame
Flexibility
Time Frame: two weeks
Flexibility will be assessed with the sit-and-reach test using an adjustable sit-and-reach bench (Adjustable Sit-and-Reach Flexibility Tester, Lafayette Instrument Company, Lafayette IN, USA). The sit-and-reach test is a valid and reliable method used to assess flexibility in many studies. First, the sit-and-reach bench placed on the mat will be fixed to the wall, and the players will be asked to place the soles of their feet on the sit-reach bench with their knees completely straight on the mat. Then, after one trial, players will be asked to reach forward as far as possible three times without bending their knees, and the average of the three assessments will be used for analysis.
two weeks

Secondary Outcome Measures

Secondary Outcome Measures

In a clinical study's protocol, a planned outcome measure that is not as important as the primary outcome measure for evaluating the effect of an intervention but is still of interest. Most clinical studies have more than one secondary outcome measure.
Outcome Measure
Measure Description
Time Frame
Dynamic balance
Time Frame: two weeks
Dynamic balance will be assessed with the Y balance test. Before the assessment, the players will be performed three trials each with 30-second rest intervals for the dominant extremity, and after the trials, the players will be given a five-minute recovery period. During the assessment after the recovery process, to ensure standardization, the players will be asked to position their dominant extremity at the centre of the junction of the measuring tapes, lie on the measuring tape with their non-dominant extremity, extending as far as possible in the anterior, posterolateral, and posteromedial directions, and touch the furthest point they could reach with their toes. This procedure will be performed by players three times with 30-second rest intervals. The greater reach distance for each direction will be calculated with the formula [(reaching distance/lower extremity length) x 100 = percentage of the maximum reaching distance)], and will be normalised with the extremity length.
two weeks
Vertical jump
Time Frame: two weeks
Vertical jump will be assessed with the Performanz JumpR, a valid and reliable device for assessing different jump performances.This device measures jump height based on the individual's flight time using the equation (jump height= 980.6653(flight time/1000.0)2/8). It also calculates anaerobic power using the individual's weight, flight time, and contact time using the equation (anaerobic power=weight x [9.813(flight time/2000,000)/(contact time/1000)]). For each jump, subjects will be instructed to jump as high as possible and keep their hands on their hips. There will be 1 minute of rest between jumps. All athletes will be received instructions to maximize their jump height and were verbally encouraged to exert maximum effort during all jump trials. The average of the three assessments will be used for analysis.
two weeks

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Sponsor

The organization or person who initiates the study and who has authority and control over the study.
Celal Bayar University

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

Study Start

The actual date on which the first participant was enrolled in a clinical study. The "anticipated" study start date is the date that the researchers think will be the study start date.
May 20, 2025

Primary Completion (Actual)

Primary Completion

The date on which the last participant in a clinical study was examined or received an intervention to collect final data for the primary outcome measure. Whether the clinical study ended according to the protocol or was terminated does not affect this date. For clinical studies with more than one primary outcome measure with different completion dates, this term refers to the date on which data collection is completed for all the primary outcome measures. The "anticipated" primary completion date is the date that the researchers think will be the primary completion date for the study.
June 5, 2025

Study Completion (Actual)

Study Completion

The date on which the last participant in a clinical study was examined or received an intervention/treatment to collect final data for the primary outcome measures, secondary outcome measures, and adverse events (that is, the last participant's last visit). The "anticipated" study completion date is the date that the researchers think will be the study completion date.
June 5, 2025

Study Registration Dates

First Submitted

First Submitted

The date on which the study sponsor or investigator first submitted a study record to ClinicalTrials.gov. There is typically a delay of a few days between the first submitted date and the record's availability on ClinicalTrials.gov (the first posted date).
May 20, 2025

First Submitted That Met QC Criteria

First Submitted That Met QC Criteria

The date on which the study sponsor or investigator first submits a study record that is consistent with National Library of Medicine (NLM) quality control (QC) review criteria. The sponsor or investigator may need to revise and submit a study record one or more times before NLM's QC review criteria are met. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
May 20, 2025

First Posted (Actual)

First Posted

The date on which the study record was first available on ClinicalTrials.gov after National Library of Medicine (NLM) quality control (QC) review has concluded. There is typically a delay of a few days between the date the study sponsor or investigator submitted the study record and the first posted date.
May 29, 2025

Study Record Updates

Last Update Posted (Actual)

Last Update Posted

The most recent date on which changes to a study record were made available on ClinicalTrials.gov. There may be a delay between when the changes were submitted to ClinicalTrials.gov by the study's sponsor or investigator (the last update submitted date) and the last update posted date.
June 27, 2025

Last Update Submitted That Met QC Criteria

Last Update Submitted That Met QC Criteria

The most recent date on which the study sponsor or investigator submitted changes to a study record that are consistent with National Library of Medicine (NLM) quality control (QC) review criteria. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
June 26, 2025

Last Verified

Last Verified

The most recent date on which the study sponsor or investigator confirmed the information about a clinical study on ClinicalTrials.gov as accurate and current. If a study with a recruitment status of recruiting; not yet recruiting; or active, not recruiting has not been confirmed within the past 2 years, the study's recruitment status is shown as unknown.
June 1, 2025

More Information

Terms related to this study

Keywords

Other Study ID Numbers

Other Study ID Numbers

Identifiers or ID numbers other than the NCT number that are assigned to a clinical study by the study's sponsor, funders, or others. These numbers may include unique identifiers from other trial registries and National Institutes of Health grant numbers.
  • CBU-FTR-ES-O6

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

IPD Plan Description

There is no plan to make individual participant data (IPD) available to other researchers.

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Cookie Settings

We use cookies to ensure that we give you the best experience on our website. For more details carefully read our Privacy and Cookies Policy. ...>>>You can change your preferences or withdraw your consent at any time by deleting the cookies from your website or computer as described in the policy. Please accept it and choose your preferences by ticking the corresponding boxes in the "Manage Settings" section below. Please carefully read our Terms of Service before you proceed with using any part of this website.
«Manage Settings